DNLI News and Press, Denali Therapeutics Inc. From 08/09/20

COVID-19 Pandemic BioKangtai (SHZ: 300601), a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's (AZN) COVID-19 vaccine in China. The candidate is an adenovirus vector-based COVID-19 vaccine that was created by Oxford University and partnered b...

Denali Therapeutics (NASDAQ: DNLI ) : Q2 GAAP EPS of -$0.56 beats by $0.04 . More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today repo...

Illumina stock tumbles as quarterly numbers decline Illumina Inc. ( ILMN ) reported its second quarter financial results. However, due to various factors including the pandemic outbreak, the numbers were not too good. The company also provided updates about business operations including ...

Gainers:  ADiTx Therapeutics (NASDAQ: ADTX ) +102% . More news on: ADiTx Therapeutics, Inc., American Virtual Cloud Technologies, Inc., NuZee, Inc., Stocks on the move, , Read more ...

Denali Therapeutics (NASDAQ: DNLI ) jumps  33%  premarket on increased volume in reaction to its agreement with Biogen (NASDAQ: BIIB ) to co-develop and co-commercialize its small molecule leucine-rich repeat kinase 2 (LRRK2) inhibitors for the potential treatment of Parkinso...

DNL151 selected to advance into two late stage studies in Parkinson’s disease in patients with a kinase activating mutation in LRRK2 and in patients with sporadic disease Denali and collaboration partner Biogen are finalizing DNL151 clinical development plans and intend to comm...

Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement disorders Biogen to receive exclusive option rights to two programs for neuro...

Denali Therapeutics ( DNLI +1.5% ) announces that collaboration partner Sanofi ( SNY -0.7% ) has started dosing in a Phase 1b clinical trial evaluating DNL758 (dubbed SAR443122 by Sanofi) in hospitalized patients with severe COVID-19 lung disease. More news on: Denali Therapeutics ...

Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19 DNL758, discovered by Denali and partnered with Sanofi, is a small molecule inhibitor of RIPK1 that does not...